rhPSMA

rhPSMA (radiohybrid Prostate-Specific Membrane Antigen) is a class of radiopharmaceutical agents developed by Scintomics and Blue Earth Diagnostics (a Bracco company) for the management of prostate cancer. The technology utilizes a "radiohybrid" (rh) approach, where a single chemical scaffold can be labeled with either a diagnostic radioisotope (e.g., Fluorine-18) or a therapeutic radioisotope (e.g., Lutetium-177 or Actinium-225) without altering its biological targeting properties. The lead diagnostic agent, rhPSMA-7.3 (flotufolastat F 18), was FDA-approved in 2023 under the brand name Posluma for PET imaging of PSMA-positive lesions in men with prostate cancer. The therapeutic program, including candidates like rhPSMA-10.1, is designed to deliver targeted radiation to PSMA-expressing prostate cancer cells, particularly in patients with metastatic castration-resistant prostate cancer (mCRPC).

Brand names

Posluma

Other names

flotufolastat F 18flotufolastatradiohybrid PSMA18F-rhPSMA-7.3177Lu-rhPSMA-10.1